Potential use of cannabimimetics in the treatment of cancer

Mechoulam R (1986) The pharmacohistory of Cannabis sativa. In: R Mechoulam (ed.): Cannabis as therapeutic agents. CRC Press, Roca Raton, FL, 1–19Google Scholar

Williamson EM, Evans FJ (2000) Cannabinoids in clinical practice. Drugs 60: 1303–1314PubMedGoogle Scholar

Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646–1647CrossRefGoogle Scholar

Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11: 137–143CrossRefPubMedGoogle Scholar

Pertwee RG (1997) Pharmacology of cannabinoid CB₁ and CB₂ receptors. Pharmacol Ther 74: 129–180CrossRefPubMedGoogle Scholar

Di Marzo V (1998) ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possble physiopathological relevance. Biochim Biophys Acta 1392: 153–175PubMedGoogle Scholar

McAllister SD, Glass M (2002) CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66: 161–171CrossRefPubMedGoogle Scholar

Paria BC, Das SK, Dey SK (1995) The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci USA 92: 9460–9464PubMedGoogle Scholar

Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ (1999) Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33: 181–191CrossRefPubMedGoogle Scholar

Mechoulam R, Hanuš L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43CrossRefPubMedGoogle Scholar

Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949PubMedGoogle Scholar

Mechoulam R, Ben-Shabat S, Hanuš L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90CrossRefPubMedGoogle Scholar

Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89–97CrossRefPubMedGoogle Scholar

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564CrossRefPubMedGoogle Scholar

Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65CrossRefPubMedGoogle Scholar

Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686–691CrossRefPubMedGoogle Scholar

Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ et al. (2003) Cloning of the first snl-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463–468CrossRefPubMedGoogle Scholar

Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69: 631–638PubMedGoogle Scholar

Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83–87CrossRefPubMedGoogle Scholar

Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272: 27218–27223CrossRefPubMedGoogle Scholar

Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35: 607–634CrossRefPubMedGoogle Scholar

Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873–884CrossRefPubMedGoogle Scholar

Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296: 678–682CrossRefPubMedGoogle Scholar

Guzman M, Sanchez C, Galve-Roperh I (2001) Control of the cell survival/death decision by cannabinoids. J Mol Med 78: 613–625CrossRefPubMedGoogle Scholar

Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB₂ receptor-mediated, cytokine-dependent pathway. J Immunol 165: 373–380PubMedGoogle Scholar

Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64: 1943–1950PubMedGoogle Scholar

Sanchez MG, Sanchez AM, Ruiz-Llorente L, Diaz-Laviada I (2003) Enhancement of androgen receptor expression induced by R-methanandamide in prostate LNCaP cells. FEBS Lett 555: 561–566CrossRefPubMedGoogle Scholar

Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. JNatl Cancer Inst 55: 597–602Google Scholar

(1996) Toxicology and carcinogenesis studies of 1-trans-delta-9-tetrahydrocannabinol in F344N/N rats and BC63F1 mice. National Institutes of Health National Toxicology Program, NIH Publication No. 97-3362Google Scholar

De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95: 8375–8380CrossRefPubMedGoogle Scholar

Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V (1999) Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463: 235–240CrossRefPubMedGoogle Scholar

Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118–126CrossRefPubMedGoogle Scholar

Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 2745–2747PubMedGoogle Scholar

Rueda D, Navarro B, Martinez-Serrano A, Guzman M, Galve-Roperh I (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 277: 46645–46650CrossRefPubMedGoogle Scholar

Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111: 43–50CrossRefPubMedGoogle Scholar

Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 1–12CrossRefPubMedGoogle Scholar

Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003) Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771–1773PubMedGoogle Scholar

Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, Guzman M (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61: 5784–5789PubMedGoogle Scholar

McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M (2002) Targeting CB₂ cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627–634CrossRefPubMedGoogle Scholar

Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436: 6–10CrossRefPubMedGoogle Scholar

Ruiz L., Miguel A, Diaz-Laviada I (1999) Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458: 400–404CrossRefPubMedGoogle Scholar

Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313–319CrossRefPubMedGoogle Scholar

Gomez del Pulgar T, Velasco G, Sanchez C, Haro A, Guzman M (2002) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363: 183–188CrossRefPubMedGoogle Scholar

Ramer R, Weinzierl U, Schwind B, Brune K, Hinz B (2003) Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 64: 1189–1198CrossRefPubMedGoogle Scholar

Guzman M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745–755CrossRefPubMedGoogle Scholar

Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett 472: 39–44CrossRefPubMedGoogle Scholar

Sarker KP, Biswas KK, Rosales JL, Yamaji K, Hashiguchi T, Lee KY, Maruyama I (2003) Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-2. J Neurochem 87: 1345–1353PubMedGoogle Scholar

Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS (2000) Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60: 490–498PubMedGoogle Scholar

Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, Lin M, Meisheng L, Junshan Y, Chengchao S (2002) A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 277: 43137–43142CrossRefPubMedGoogle Scholar

Casanova ML, Larcher F, Casanova B, Murillas R, Fernandez-Acenero MJ, Villanueva C, Martinez-Palacio J, Ullrich A, Conti CJ, Jorcano JL (2002) A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62: 3402–3407PubMedGoogle Scholar

Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529–531PubMedGoogle Scholar

Joseph J, Niggemann B, Zaenker KS, Entschladen F (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53: 723–728CrossRefPubMedGoogle Scholar

Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grubler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V et al. (2001) Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86: 2687–2696CrossRefPubMedGoogle Scholar

Maccarrone M, Attina M, Cartoni A, Bari M, Finazzi-Agrò (2001) A Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76: 594–601CrossRefPubMedGoogle Scholar

Schmid PC, Wold LE, Krebsbach RJ, Berdyshev EV, Schmid HH (2002) Anandamide and other N-acylethanolamines in human tumors. Lipids 37: 907–912PubMedGoogle Scholar

Maccarrone M (2004) Levels of N-acylethanolamines in human tumors: in search of reliable data. Lipids 39: 193–194PubMedGoogle Scholar

Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D’argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677–687CrossRefPubMedGoogle Scholar

Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L, Yamamoto S, Di Marzo V (1998) Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur J Biochem 254: 634–642CrossRefPubMedGoogle Scholar

Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L (2001) Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358: 249–255CrossRefPubMedGoogle Scholar

De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V (2002) Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16: 297–302CrossRefPubMedGoogle Scholar

Pertwee RG (2004) New pharmacological targets for cannabinoids. Curr Neuropharmacol 2: 9–29CrossRefGoogle Scholar

Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agrò A (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 31938–31945CrossRefPubMedGoogle Scholar

Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159–212PubMedGoogle Scholar

Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66: 377–391CrossRefPubMedGoogle Scholar

Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M, Di Marzo V (1999) Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262: 275–284CrossRefPubMedGoogle Scholar

Contassot E, Tenan M, Schnuriger V, Pelte MF, Dietrich PY (2004) Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93: 182–188CrossRefPubMedGoogle Scholar

Jacobsson SO, Wallin T, Fowler CJ (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299: 951–959PubMedGoogle Scholar

Grant ER, Dubin AE, Zhang SP, Zivin RA, Zhong Z (2002) Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell death. J Pharmacol Exp Ther 300: 9–17CrossRefPubMedGoogle Scholar

Biro T, Brodie C, Modarres S, Lewin NE, Acs P, Blumberg PM (1998) Specific vanilloid responses in C6 rat glioma cells. Brain Res Mol Brain Res 56: 89–98CrossRefPubMedGoogle Scholar

Macho A, Calzado MA, Munoz-Blanco J, Gomez-Diaz C, Gajate C, Mollinedo F, Navas P, Munoz E (1999) Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ 6: 155–165CrossRefPubMedGoogle Scholar

Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Schiano Moriello A, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852CrossRefPubMedGoogle Scholar

Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427: 260–265CrossRefPubMedGoogle Scholar

Carchman RA, Harris LS, Munson AE (1976) The inhibition of DNA synthesis by cannabinoids. Cancer Res 36: 95–100PubMedGoogle Scholar

Jacobsson SO, Rongard E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60: 1807–1813CrossRefPubMedGoogle Scholar

Mechoulam R, Hanuš L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43CrossRefPubMedGoogle Scholar

Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838–845CrossRefPubMedGoogle Scholar

Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 44: 1767–1773CrossRefPubMedGoogle Scholar

Baek SH, Kim YO, Kwag JS, Choi KE, Jung WY, Han DS (1998) Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharmacol Res 21: 353–356Google Scholar

Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R, Litofsky NS, Burstein S (2001) Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 62: 755–763CrossRefPubMedGoogle Scholar

Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB (2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108: 95–102CrossRefPubMedGoogle Scholar

Guzman M, Galve-Roperh I, Sanchez C (2001) Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 22: 19–22CrossRefPubMedGoogle Scholar

Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G (2002) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277: 36527–36533CrossRefPubMedGoogle Scholar

Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742–9753PubMedGoogle Scholar

van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26: 317–346CrossRefPubMedGoogle Scholar

Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42: 327–360PubMedGoogle Scholar

Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003) CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62–67CrossRefPubMedGoogle Scholar

Bifulco M, Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8: 547–550CrossRefPubMedGoogle Scholar

Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71S–81SPubMedGoogle Scholar

(2003) Cannabis-based medicines—GW pharmaceuticals: high CBD, high THC, medicinal cannabis—GW pharmaceuticals, THC:CBD. Drugs R D 4: 306–309Google Scholar

Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR (2000) O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br JPharmacol 129: 1577–1584CrossRefGoogle Scholar

Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Invest Drugs 9: 1553–1571CrossRefGoogle Scholar

Di Carlo G, Izzo AA (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Invest Drugs 12: 39–49CrossRefGoogle Scholar

Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J 323: 16–21Google Scholar

Walsh 2003 and James JS (2000) Marijuana safety study completed: weight gain, no safety problems. AIDS Treat News 348: 3–4PubMedGoogle Scholar

Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137: 589–596CrossRefPubMedGoogle Scholar

Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566–G576PubMedGoogle Scholar

Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 69: 239–249CrossRefPubMedGoogle Scholar

Darmani NA, Johnson JC (2004) Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201–212CrossRefPubMedGoogle Scholar

Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75: 777–787CrossRefPubMedGoogle Scholar

Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, Mutoh S (2002) Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 442: 273–278CrossRefPubMedGoogle Scholar

Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136: 550–557CrossRefPubMedGoogle Scholar

Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825CrossRefPubMedGoogle Scholar

Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423–431CrossRefPubMedGoogle Scholar

Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE et al. (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20: 567–573CrossRefPubMedGoogle Scholar

Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2: 50–55CrossRefPubMedGoogle Scholar

Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198–12203CrossRefPubMedGoogle Scholar

Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63: 569–611CrossRefPubMedGoogle Scholar

Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2: 201–209CrossRefPubMedGoogle Scholar

Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J 323: 13–16Google Scholar

Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105: 79–88CrossRefPubMedGoogle Scholar

Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317–1324CrossRefPubMedGoogle Scholar

Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395–1398CrossRefPubMedGoogle Scholar

Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76–81CrossRefPubMedGoogle Scholar

Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534CrossRefPubMedGoogle Scholar

Bisogno T, Melck D, Bobrov MYu, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351: 817–824CrossRefPubMedGoogle Scholar

Jones S, Howl J (2003) Cannabinoid receptor systems: therapeutic targets for tumour intervention. Expert Opin Ther Targets 7: 749–758CrossRefPubMedGoogle Scholar

Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606–1608PubMedGoogle Scholar

Contassot E, Wilmotte R, Tenan M, Belkouch MC, Schnuriger V, de Tribolet N, Burkhardt K, Dietrich PY (2004) Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. JNeuropathol Exp Neurol 63: 956–963Google Scholar

Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. (2004) Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64: 5617–5623PubMedGoogle Scholar

Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB (2004) 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64: 8826–8830PubMedGoogle Scholar